Dinoseb

CASRN 88-85-7

  • IRIS Summary (PDF) (12 pp, 111 K)
  • Status: Dinoseb is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (12 pp, 111 K) last updated: 01/31/1987

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
1 x10-3 Developmental Decreased fetal weight LEL : 1
mg/kg-day
1000 Low

Reference Concentration for Inhalation Exposure (RfC) (PDF) (12 pp, 111 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (12 pp, 111 K) last updated: 08/01/1989

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Dinoseb was not observed to be carcinogenic in two inadequate studies in rats and in mice. In a third study, an increase in benign liver tumors in female mice was not considered to be treatment-related. The increase was much lower in the high dose than the mid dose, there were no decreases in time to tumor, nor any evidence of any of the potentially predisposing lesions in the liver such as hypertrophy, hyperplasia or degeneration which are often associated with known hepatocellular carcinogens.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (12 pp, 111 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (12 pp, 111 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.